Aurora Cannabis Inc (TSE: ACB) (NASDAQ: ACB) (FRA: 21P) Chief Financial Officer Simona King just announced a major strategic pivot, revealing that the company will be shifting to focus “solely” on medical cannabis operations. She highlighted the development at this week’s TD Cowen Health Care Conference in Boston, Massachusetts.
Aurora now aims to prioritize high-margin, regulated international markets like Germany, Australia and Poland while exiting lower-margin segments in Canada’s consumer cannabis space.
The move includes divesting a plant propagation unit to streamline operations and boost profitability. Furthermore, the company has invested in capacity expansions, such as its licensed German cultivation facility, and partnerships to enhance patient access in Australia.
King emphasized that this medical-first approach aligns with pharmaceutical-like markets, where regulations ensure stability and higher margins.
Recent financial highlights have reinforced the rationale behind this move. In the fiscal third quarter of 2026, Aurora reported a 7 per cent year-over-year revenue increase to C$94 million, with medical cannabis accounting for 81 per cent of total revenue and 95 per cent of adjusted gross profit.
King speaks at the TD Cowen Health Care Conference on Monday. Photo credit: Aurora Cannabis
Aurora faces challenges in Canada
The licensed producer has grappled with intense competition and oversupply in Canada, where recreational cannabis legalization in 2018 flooded the market and drove down prices.
High excise taxes and strict regulations further squeezed margins, prompting the company to scale back domestic consumer operations.
CEO Miguel Martin noted during a recent earnings call that the Canadian consumer segment no longer suits Aurora’s profile, leading to exits from select low-margin sectors within the country.
“Both the margins and the overall profile of it really does not work well for a company like Aurora,” he said in an interview with BNN Bloomberg last month, adding that the Canadian company’s future looked much brighter in other countries.
Aurora’s stock has plummeted 96 per cent since 2021, reflecting persistent net losses and a negative gross margin of -126 per cent. Factors like these have pushed Aurora to reallocate resources toward more profitable global medical avenues.
Read more: Canadian petition aims to make minimum cannabis consumption age 25, ban edibles
Nasdaq event draws criticism; analysts get bullish
Aurora rang the Nasdaq closing bell on Feb. 18, celebrating its medical-focused and global ambitions. The cannabis producer alluded to what King explained at this week’s event in a news release on Feb. 12, saying that ringing the bell would signify its “evolution into a medical-first, globally focused cannabis company.”
However, the event sparked debate among critics who questioned a Canadian cannabis company’s prominence on a major U.S. exchange amid ongoing federal restrictions.
“How is this allowed while USA cannabis is schedule 1 and cannot be listed or acknowledged by NASDAQ?” commented one X user in a popular post.
With regard to Aurora’s future outlook, analysts are optimistic. Canaccord Genuity Group Inc (TSE: CF) (OTCMKTS: CCORF) (FRA: C6U) initiated a Buy rating and C$10 price target in February, citing Aurora’s international medical leadership.
Consensus forecasts suggest a 66 per cent upside to an average target of C$6.38, driven by revenue growth and perception of the stock being undervalued.
Read more: Aurora Cannabis expands Australian footprint with medical distribution deal
Follow Rowan Dunne on LinkedIn
rowan@mugglehead.com
